| 11. |
|
|
| 12. |
|
|
| 13. |
- Maercker, Matthias, et al.
(författare)
-
L-band (3.5 μm) IR-excess in massive star formation. II. RCW 57/NGC 3576
- 2006
-
Ingår i: Astronomy & Astrophysics. - : EDP Sciences. - 0004-6361 .- 1432-0746. ; 450:1, s. 253-263
-
Tidskriftsartikel (refereegranskat)abstract
- Context: .We present a JHKsL survey of the massive star forming region RCW 57 (NGC 3576) based on L-band data at 3.5 μm taken with SPIREX (South Pole Infrared Explorer), and 2MASS JHKs data at 1.25-2.2 μm. This is the second of two papers, the first one concerning a similar JHKsL survey of 30 Doradus.Aims: .Colour-colour and colour-magnitude diagrams are used to detect sources with infrared excess. This excess emission is interpreted as coming from circumstellar disks, and hence gives the cluster disk fraction (CDF). Based on the CDF and the age of RCW 57, it is possible to draw conclusions on the formation and early evolution of massive stars.Methods: .The infrared excess is detected by comparing the locations of sources in JHKsL colour-colour and L vs. (K_s-L) colour-magnitude diagrams to the reddening band due to interstellar extinction.Results: .A total of 251 sources were detected. More than 50% of the 209 sources included in the diagrams have an infrared excess.Conclusions: .Comparison with other JHKsL surveys, including the results on 30 Doradus from the first paper, support a very high initial disk fraction (>80%) even for massive stars, although there is an indication of a possible faster evolution of circumstellar disks around high mass stars. 33 sources only found in the L-band indicate the presence of heavily embedded, massive Class I protostars. We also report the detection of diffuse PAHs emission throughout the RCW 57 region.
|
|
| 14. |
- Mega, JL, et al.
(författare)
-
Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46: a randomised, double-blind, phase II trial
- 2009
-
Ingår i: Lancet. - 0140-6736. ; 374:9683, s. 29-38
-
Tidskriftsartikel (refereegranskat)abstract
- Rivaroxaban is an oral direct factor Xa inhibitor that has been effective in prevention of venous thromboembolism in patients undergoing elective orthopaedic surgery. However, its use after acute coronary syndromes has not been investigated. In this setting, we assessed the safety and efficacy of rivaroxaban and aimed to select the most favourable dose and dosing regimen. METHODS: In this double-blind, dose-escalation, phase II study, undertaken at 297 sites in 27 countries, 3491 patients stabilised after an acute coronary syndrome were stratified on the basis of investigator decision to use aspirin only (stratum 1, n=761) or aspirin plus a thienopyridine (stratum 2, n=2730). Participants were randomised within each strata and dose tier with a block randomisation method at 1:1:1 to receive either placebo or rivaroxaban (at doses 5-20 mg) given once daily or the same total daily dose given twice daily. The primary safety endpoint was clinically significant bleeding (TIMI major, TIMI minor, or requiring medical attention); the primary efficacy endpoint was death, myocardial infarction, stroke, or severe recurrent ischaemia requiring revascularisation during 6 months. Safety analyses included all participants who received at least one dose of study drug; efficacy analyses were by intention to treat. This study is registered with ClinicalTrials.gov, number NCT00402597. FINDINGS: Three patients in stratum 1 and 26 in stratum 2 never received the study drug. The risk of clinically significant bleeding with rivaroxaban versus placebo increased in a dose-dependent manner (hazard ratios [HRs] 2.21 [95% CI 1.25-3.91] for 5 mg, 3.35 [2.31-4.87] for 10 mg, 3.60 [2.32-5.58] for 15 mg, and 5.06 [3.45-7.42] for 20 mg doses; p<0.0001). Rates of the primary efficacy endpoint were 5.6% (126/2331) for rivaroxaban versus 7.0% (79/1160) for placebo (HR 0.79 [0.60-1.05], p=0.10). Rivaroxaban reduced the main secondary efficacy endpoint of death, myocardial infarction, or stroke compared with placebo (87/2331 [3.9%] vs 62/1160 [5.5%]; HR 0.69, [95% CI 0.50-0.96], p=0.0270). The most common adverse event in both groups was chest pain (248/2309 [10.7%] vs 118/1153 [10.2%]). INTERPRETATION: The use of an oral factor Xa inhibitor in patients stabilised after an acute coronary syndrome increases bleeding in a dose-dependent manner and might reduce major ischaemic outcomes. On the basis of these observations, a phase III study of low-dose rivaroxaban as adjunctive therapy in these patients is underway.
|
|
| 15. |
|
|
